Toll-like receptor signalling and their therapeutic targeting in colorectal cancer

International Immunopharmacology

Volumn 16, Issue 2, 2013, Pages 199-209

  Moossavi, Shirin ^a   Rezaei, Nima ^b,c,d  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Colorectal cancer; Susceptibility; Toll like receptors; Tumorigenesis Treatment Prognosis

Indexed keywords

BCG VACCINE; CD133 ANTIGEN; COMPLEMENTARY DNA; CYCLOPHOSPHAMIDE; MEMBRANE RECEPTOR; MICRORNA; MYELOID DIFFERENTIATION FACTOR 88; NONSTEROID ANTIINFLAMMATORY AGENT; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 6; TOLL LIKE RECEPTOR 7;

CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CANCER STAGING; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CHROMOSOMAL INSTABILITY; COLORECTAL CANCER; COMPARATIVE GENOMIC HYBRIDIZATION; DENDRITIC CELL; DISEASE FREE SURVIVAL; DNA MICROARRAY; DRUG TARGETING; GENE EXPRESSION; GENE MUTATION; GENETIC ASSOCIATION; GENETIC VARIABILITY; HUMAN; IMMUNE RESPONSE; IMMUNOSURVEILLANCE; IMMUNOTHERAPY; MICROFLORA; NONHUMAN; OVERALL SURVIVAL; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM;

ANIMALS; COLORECTAL NEOPLASMS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICRORNAS; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTORS;

EID: 84877826018     PISSN: 15675769     EISSN: 18781705     Source Type: Journal    
DOI: 10.1016/j.intimp.2013.03.017     Document Type: Review

References (121)

1. F. Guarner, and J.R. Malagelada Gut flora in health and disease Lancet 361 2003 512 519 (Pubitemid 36173720)
2. D. Artis Epithelial-cell recognition of commensal bacteria and maintenance of immune homeostasis in the gut Nat Rev Immunol 8 2008 411 420 (Pubitemid 351733416)
3. C.D. Packey, and R.B. Sartor Interplay of commensal and pathogenic bacteria, genetic mutations, and immunoregulatory defects in the pathogenesis of inflammatory bowel diseases J Intern Med 263 2008 597 606 (Pubitemid 351678591)
4. T. Kawai, and S. Akira TLR signaling Semin Immunol 19 2007 24 32 (Pubitemid 46498752)
5. M.T. Abreu Toll-like receptor signalling in the intestinal epithelium: how bacterial recognition shapes intestinal function Nat Rev Immunol 10 2010 131 144
6. E. Cario, and D.K. Podolsky Differential alteration in intestinal epithelial cell expression of toll-like receptor 3 (TLR3) and TLR4 in inflammatory bowel disease Infect Immun 68 2000 7010 7017 (Pubitemid 32463415)
7. L. Frolova, P. Drastich, P. Rossmann, K. Klimesova, and H. Tlaskalova-Hogenova Expression of Toll-like receptor 2 (TLR2), TLR4, and CD14 in biopsy samples of patients with inflammatory bowel diseases: upregulated expression of TLR2 in terminal ileum of patients with ulcerative colitis J Histochem Cytochem 56 2008 267 274 (Pubitemid 351272998)
8. E. Cario Toll-like receptors in inflammatory bowel diseases: a decade later Inflamm Bowel Dis 16 2010 1583 1597
9. M. Fukata, A. Chen, A. Vamadevan, J. Cohen, K. Breglio, and S. Krishnareddy Toll-like receptor-4 (TLR4) promotes the development of colitis-associated colorectal tumors Gastroenterology 133 2007 1869 1881
10. S. Rakoff-Nahoum, and R. Medzhitov Toll-like receptors and cancer Nat Rev Cancer 9 2009 57 63
11. M. Hedayat, K. Takeda, and N. Rezaei Prophylactic and therapeutic implications of Toll-like receptor ligands Med Res Rev 32 2012 294 325
12. M. Hedayat, M.G. Netea, and N. Rezaei Targeting of Toll-like receptors: a decade of progress in combating infectious diseases Lancet Infect Dis 11 2011 702 712
13. N. Rezaei Therapeutic targeting of pattern-recognition receptors Int Immunopharmacol 6 2006 863 869
14. C.N. Bernstein, J.F. Blanchard, E. Kliewer, and A. Wajda Cancer risk in patients with inflammatory bowel disease: a population-based study Cancer 91 2001 854 862 (Pubitemid 32173312)
15. M.E. Hope, G.L. Hold, R. Kain, and E.M. El-Omar Sporadic colorectal cancer - role of the commensal microbiota FEMS Microbiol Lett 244 2005 1 7 (Pubitemid 40261172)
16. S. Moossavi, and F. Bishehsari Inflammation in sporadic colorectal cancer Arch Iran Med 15 2012 166 170
17. H. Shaked, L.J. Hofseth, A. Chumanevich, A.A. Chumanevich, J. Wang, and Y. Wang Chronic epithelial NF-κB activation accelerates APC loss and intestinal tumor initiation through iNOS up-regulation Proc Natl Acad Sci U S A 109 2012 14007 14012
18. M. Fukata, Y. Hernandez, D. Conduah, J. Cohen, A. Chen, and K. Breglio Innate immune signaling by Toll-like receptor-4 (TLR4) shapes the inflammatory microenvironment in colitis-associated tumors Inflamm Bowel Dis 15 2009 997 1006
19. M. Fukata, L. Shang, R. Santaolalla, J. Sotolongo, C. Pastorini, and C. España Constitutive activation of epithelial TLR4 augments inflammatory responses to mucosal injury and drives colitis-associated tumorigenesis Inflamm Bowel Dis 17 2011 1464 1473
20. E.L. Lowe, T.R. Crother, S. Rabizadeh, B. Hu, H. Wang, and S. Chen Toll-like receptor 2 signaling protects mice from tumor development in a mouse model of colitis-induced cancer PLoS One 5 9 2010 e13027 10.1371/journal.pone. 0013027
21. S.A. Forbes, N. Bindal, S. Bamford, C. Cole, C.Y. Kok, and D. Beare COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer Nucleic Acids Res 39 2011 D945 D950
22. Y. Nihon-Yanagi, K. Terai, T. Murano, T. Matsumoto, and S. Okazumi Tissue expression of Toll-like receptors 2 and 4 in sporadic human colorectal cancer Cancer Immunol Immunother 61 2012 71 77
23. R. Cammarota, V. Bertolini, G. Pennesi, E.O. Bucci, O. Gottardi, and C. Garlanda The tumor microenvironment of colorectal cancer: stromal TLR-4 expression as a potential prognostic marker J Transl Med 8 2010 112
24. E.L. Wang, Z.R. Qian, M. Nakasono, T. Tanahashi, K. Yoshimoto, and Y. Bando High expression of Toll-like receptor 4/myeloid differentiation factor 88 signals correlates with poor prognosis in colorectal cancer Br J Cancer 102 2010 908 915
25. M. Grimm, M. Kim, A. Rosenwald, U. Heemann, C.T. Germer, and A.M. Waaga-Gasser Toll-like receptor (TLR) 7 and TLR8 expression on CD133 + cells in colorectal cancer points to a specific role for inflammation-induced TLRs in tumourigenesis and tumour progression Eur J Cancer 46 2010 2849 2857
26. N. Eiró, L. González, L.O. González, A. Andicoechea, M. Fernández-Díaz, and A. Altadill Study of the expression of Toll-like receptors in different histological types of colorectal polyps and their relationship with colorectal cancer J Clin Immunol 32 2012 848 854
27. H. Xu, Q. Wu, S. Dang, M. Jin, J. Xu, and Y. Cheng Alteration of CXCR7 expression mediated by TLR4 promotes tumor cell proliferation and migration in human colorectal carcinoma PLoS One 6 12 2011 e27399 10.1371/journal.pone. 0027399
28. D. Horst, J. Budczies, T. Brabletz, T. Kirchner, and F. Hlubek Invasion associated up-regulation of nuclear factor kappaB target genes in colorectal cancer Cancer 115 2009 4946 4958
29. A.P. Femia, A. Swidsinski, P. Dolara, M. Salvadori, A. Amedei, and G. Caderni Mucin depleted foci, colonic preneoplastic lesions lacking Muc2, show up-regulation of Tlr2 but not bacterial infiltration PLoS One 7 1 2012 e29918 10.1371/journal.pone.0029918
30. M.D. Neal, C.P. Sodhi, I. Yazji, A.M. Russo, R. Siggers, and H. Jia Toll-like receptor 4 (TLR4) is expressed on intestinal stem cells and inhibits stem cell proliferation in the pathogenesis of intestinal inflammation J Am Coll Surg 213 2011 S85
31. S.V. Shmelkov, J.M. Butler, A.T. Hooper, A. Hormigo, J. Kushner, and T. Milde CD133 expression is not restricted to stem cells, and both CD133 + and CD133 - metastatic colon cancer cells initiate tumors J Clin Invest 118 2008 2111 2120 (Pubitemid 351872330)
32. G.C. Tseng, D. Ghosh, and E. Feingold Comprehensive literature review and statistical considerations for microarray meta-analysis Nucleic Acids Res 40 2012 3785 3799
33. S.K. Chan, O.L. Griffith, I.T. Tai, and S.J.M. Jones Meta-analysis of colorectal cancer gene expression profiling studies identifies consistently reported candidate biomarkers Cancer Epidemiol Biomarkers Prev 17 2008 543 552 (Pubitemid 351469203)
34. J. Cardoso, J. Boer, H. Morreau, and R. Fodde Expression and genomic profiling of colorectal cancer Biochim Biophys Acta 1775 2007 103 137 (Pubitemid 44881195)
35. E. Sagynaliev, R. Steinert, G. Nestler, H. Lippert, M. Knoch, and M.A. Reymond Web-based data warehouse on gene expression in human colorectal cancer Proteomics 5 2005 3066 3078 (Pubitemid 41176473)
36. J. Lascorz, K. Hemminki, and A. Försti Systematic enrichment analysis of gene expression profiling studies identifies consensus pathways implicated in colorectal cancer development J Carcinog 10 2011 7
37. T. Reichling, K.H. Goss, D.J. Carson, R.W. Holdcraft, C. Ley-Ebert, and D. Witte Transcriptional profiles of intestinal tumors in Apc min mice are unique from those of embryonic intestine and identify novel gene targets dysregulated in human colorectal tumors Cancer Res 65 2005 166 176 (Pubitemid 40070807)
38. N.F. Paoni, M.W. Feldman, L.S. Gutierrez, V.A. Ploplis, and F.J. Castellino Transcriptional profiling of the transition from normal intestinal epithelia to adenomas and carcinomas in the APC Min/+ mouse Physiol Genomics 15 2003 228 235 (Pubitemid 38089569)
39. N. Buchon, N.A. Broderick, M. Poidevin, S. Pradervand, and B. Lemaitre Drosophila intestinal response to bacterial infection: activation of host defense and stem cell proliferation Cell Host Microbe 5 2009 200 211
40. E.A. Misch, and T.R. Hawn Toll-like receptor polymorphisms and susceptibility to human disease Clin Sci (Lond) 114 2008 347 360 (Pubitemid 351397384)
41. S. Lindström, D.J. Hunter, H. Grönberg, P. Stattin, F. Wiklund, and J. Xu Sequence variants in the TLR4 and TLR6-1-10 genes and prostate cancer risk. Results based on pooled analysis from three independent studies Cancer Epidemiol Biomarkers Prev 19 2010 873 876
42. S. Pandey, R.D. Mittal, M. Srivastava, K. Srivastava, S. Singh, and S. Srivastava Impact of Toll-like receptors [TLR] 2 (- 196 to - 174 del) and TLR 4 (Asp299Gly, Thr399Ile) in cervical cancer susceptibility in North Indian women Gynecol Oncol 114 2009 501 505
43. K.A. Ashton, A. Proietto, G. Otton, I. Symonds, M. McEvoy, and J. Attia Toll-like receptor (TLR) and nucleosome-binding oligomerization domain (NOD) gene polymorphisms and endometrial cancer risk BMC Cancer 10 2010 382
44. S.C. Corr, and L.A.J. O'Neill Genetic variation in toll-like receptor signalling and the risk of inflammatory and immune diseases J Innate Immun 1 2009 350 357
45. M. Slattery, J. Herrick, K. Bondurant, and R. Wolff Toll-like receptor genes and their association with colon and rectal cancer development and prognosis Int J Cancer 130 2012 2974 2980
46. T. Boraska Jelavić, M. Barisić, I. Drmic Hofman, V. Boraska, E. Vrdoljak, and M. Peruzović Microsatelite GT polymorphism in the toll-like receptor 2 is associated with colorectal cancer Clin Genet 70 2006 156 160 (Pubitemid 44028102)
47. F.A. Castro, A. Försti, S. Buch, H. Kalthoff, C. Krauss, and M. Bauer TLR-3 polymorphism is an independent prognostic marker for stage II colorectal cancer Eur J Cancer 47 2011 1203 1210
48. P. Pimentel-nunes, A.L. Teixeira, C. Pereira, M. Gomes, C. Brandão, and C. Rodrigues Functional polymorphisms of Toll-like receptors 2 and 4 alter the risk for colorectal carcinoma in Europeans Dig Liver Dis 45 2013 63 69
49. D.D. Licatalosi, and R.B. Darnell Resolving RNA complexity to decipher regulatory rules governing biological networks Nat Rev Genet 11 2010 75 87
50. S. Janssens, K. Burns, J. Tschopp, and R. Beyaert Regulation of interleukin-1- and lipopolysaccharide-induced NF-κB activation by alternative splicing of MyD88 Curr Biol 12 2002 467 471 (Pubitemid 34248892)
51. S. Janssens, K. Burns, E. Vercammen, J. Tschopp, and R. Beyaert MyD88s, a splice variant of MyD88, differentially modulates NF-κB- and AP-1-dependent gene expression FEBS Lett 548 2003 103 107 (Pubitemid 37281258)
52. C.A. Wells, A.M. Chalk, A. Forrest, D. Taylor, N. Waddell, and K. Schroder Alternate transcription of the Toll-like receptor signaling cascade Genome Biol 7 2006 R10 10.1186/gb-2006-7-2-r10 (Pubitemid 43871859)
53. N.W.J. Schröder, and R.R. Schumann Single nucleotide polymorphisms of Toll-like receptors and susceptibility to infectious disease Lancet Infect Dis 5 2005 156 164 (Pubitemid 40568671)
54. C.M. Johnson, E.A. Lyle, K.O. Omueti, V.A. Stepensky, O. Yegin, and E. Alpsoy A common polymorphism impairs cell surface trafficking and functional responses of TLR1 but protects against leprosy J Immunol 178 2007 7520 7524 (Pubitemid 46898019)
55. T.R. Hawn, E.A. Misch, S.J. Dunstan, G.E. Thwaites, N.T. Lan, and H.T. Quy A common human TLR1 polymorphism regulates the innate immune response to lipopeptides Eur J Immunol 37 2007 2280 2289 (Pubitemid 47250219)
56. K.O. Omueti, D.J. Mazur, K.S. Thompson, E.A. Lyle, and R.I. Tapping The polymorphism P315L of human toll-like receptor 1 impairs innate immune sensing of microbial cell wall components J Immunol 178 2007 6387 6394 (Pubitemid 46729197)
57. D.K. Podolsky, G. Gerken, A. Eyking, and E. Cario Colitis-associated variant of TLR2 causes impaired mucosal repair due to TFF3 deficiency Gastroenterology 137 2009 209 220
58. S. Merx, M. Neumaier, H. Wagner, C.J. Kirschning, and P. Ahmad-Nejad Characterization and investigation of single nucleotide polymorphisms and a novel TLR2 mutation in the human TLR2 gene Hum Mol Genet 16 2007 1225 1232 (Pubitemid 47062718)
59. M.K. Tulic, R.J. Hurrelbrink, C.M. Prêle, I.A. Laing, J.W. Upham, and P. Le Souef TLR4 polymorphisms mediate impaired responses to respiratory syncytial virus and lipopolysaccharide J Immunol 179 2007 132 140 (Pubitemid 46986527)
60. B. Ferwerda, M.B.B. McCall, K. Verheijen, B.J. Kullberg, A.J. van der Ven, and J.W.M. Van der Meer Functional consequences of toll-like receptor 4 polymorphisms Mol Med 14 2008 346 352 (Pubitemid 351785708)
61. S. Merx, W. Zimmer, M. Neumaier, and P. Ahmad-Nejad Characterization and functional investigation of single nucleotide polymorphisms (SNPs) in the human TLR5 gene Hum Mutat 27 2006 293
62. A.V. Kubarenko, S. Ranjan, A. Rautanen, T.C. Mills, S. Wong, and F. Vannberg A naturally occurring variant in human TLR9, P99L, is associated with loss of CpG oligonucleotide responsiveness J Biol Chem 285 2010 36486 36494
63. A. Eyking, B. Ey, M. Rünzi, A.I. Roig, H. Reis, and K.W. Schmid Toll-like receptor 4 variant D299G induces features of neoplastic progression in Caco-2 intestinal cells and is associated with advanced human colon cancer Gastroenterology 141 2011 2154 2165
64. L.A. Garcia Rodriguez, and C. Huertta-Alvarez Reduced risk of colorectal cancer among long-term users of aspirin and nonaspirin nonsteroidal antiinflammatory drugs Epidemiology 12 2001 88 93 (Pubitemid 32006467)
65. P.E. Miller, P. Lazarus, S.M. Lesko, J.E. Muscat, G. Harper, and A.J. Cross Diet index-based and empirically derived dietary patterns are associated with colorectal risk J Nutr 140 2010 1267 1273
66. D.J. Harriss, G. Atkinson, A. Batterham, K. George, N. Tim Cable, and T. Reilly Lifestyle factors and colorectal cancer risk (2): a systematic review and meta-analysis of associations with leisure-time physical activity Colorectal Dis 11 2009 689 701
67. T. Pischon, P.H. Lahmann, H. Boeing, C. Friedenreich, T. Norat, and A. Tjønneland Body size and risk of colon and rectal cancer in the European Prospective Investigation Into Cancer and Nutrition (EPIC) J Natl Cancer Inst 98 2006 920 931 (Pubitemid 44018922)
68. T. Otani, M. Iwasaki, and S. Yamamoto Alcohol consumption, smoking, and subsequent risk of colorectal cancer in middle-aged and elderly Japanese men and women: japan public health center-based prospective study Cancer Epidemiol Biomarkers Prev 12 2003 1492 1500 (Pubitemid 38031754)
69. W.M. Grady Genomic instability and colon cancer Cancer Metastasis Rev 23 2004 11 27 (Pubitemid 38221594)
70. R.P. Brosens, E.J. Belt, J.C. Haan, T.E. Buffart, B. Carvalho, and H. Grabsch Deletion of chromosome 4q predicts outcome in stage II colon cancer patients Cell Oncol 34 2011 215 223
71. R. Arribas, M. Ribas, R.A. Risques, L. Masramon, and S. To Prospective assessment of allelic losses at 4p14-16 in colorectal cancer: two mutational patterns and a locus associated with poorer survival Clin Cancer Res 5 1999 3454 3459
72. H.T. Zheng, L.X. Jiang, Z.C. Lv, D.P. Li, C.Z. Zhou, and J.J. Gao Are there tumor suppressor genes on chromosome 4p in sporadic colorectal carcinoma? World J Gastroenterol 14 2008 90 94
73. B.M. Ghadimi, M. Grade, C. Mönkemeyer, B. Kulle, J. Gaedcke, and B. Gunawan Distinct chromosomal profiles in metastasizing and non-metastasizing colorectal carcinomas Cell Oncol 28 2006 273 281 (Pubitemid 44950098)
74. C.B. Diep, K. Kleivi, F.R. Ribeiro, M.R. Teixeira, O.C. Lindgjærde, and R.A. Lothe The Order of genetic events associated with colorectal cancer progression inferred from meta-analysis of copy number changes Genes Chromosomes Cancer 41 2006 31 41 (Pubitemid 46930859)
75. S.R. Quinn, and L.A. O'Neill A trio of microRNAs that control Toll-like receptor signalling Int Immunol 23 2011 421 425
76. D.M. Garcia, D. Baek, C. Shin, G.W. Bell, A. Grimson, and D.P. Bartel Weak seed-pairing stability and high target-site abundance decrease the proficiency of lys-6 and other miRNAs Nat Struct Mol Biol 18 2011 1139 1146
77. J.M. Cummins, Y. He, R.J. Leary, R. Pagliarini, L.A. Diaz Jr., and T. Sjoblom The colorectal microRNAome Proc Natl Acad Sci U S A 103 2006 3687 3692 (Pubitemid 43376616)
78. A. Piepoli, F. Tavano, M. Copetti, T. Mazza, O. Palumbo, and A. Panza Mirna expression profiles identify drivers in colorectal and pancreatic cancers PLoS One 7 3 2012 e33663 10.1371/journal.pone.0033663
79. A.N. Bartley, H. Yao, B.A. Barkoh, C. Ivan, B.M. Mishra, and A. Rashid Complex patterns of altered microRNA expression during the adenoma- adenocarcinoma sequence for microsatellite-stable colorectal cancer Clin Cancer Res 17 2011 7283 7293
80. E.R. Fearon Molecular genetics of colorectal cancer Annu Rev Pathol 6 2011 479 507
81. L.M. Coussens, and Z. Werb Inflammation and cancer Nature 420 2002 860 867 (Pubitemid 36019639)
82. B. Huang, J. Zhao, H. Li, K.L. He, Y. Chen, and S.H. Chen Toll-like receptors on tumor cells facilitate evasion of immune surveillance Cancer Res 65 2005 5009 5014 (Pubitemid 40827306)
83. S.H. Rhee, E. Im, and C. Pothoulakis Toll-like receptor 5 engagement modulates tumor development and growth in a mouse xenograft model of human colon cancer Gastroenterology 135 2008 518 528
84. L. Liu, Y.H. Li, Y.B. Niu, Y. Sun, Z.J. Guo, and Q. Li An apple oligogalactan prevents against inflammation and carcinogenesis by targeting LPS/TLR4/NF-κB pathway in a mouse model of colitis-associated colon cancer Carcinogenesis 31 2010 1822 1832
85. M. Fukuda, Y. Komiyama, K. Mitsuyama, A. Andoh, T. Aoyama, and Y. Matsumoto Prebiotic treatment reduced preneoplastic lesions through the downregulation of toll like receptor 4 in a chemo induced carcinogenic model J Clin Biochem Nutr 49 2011 57 61
86. J. Gong, J. Xu, W. Zhu, X. Gao, N. Li, and J. Li Epithelial-specific blockade of MyD88-dependent pathway causes spontaneous small intestinal inflammation Clin Immunol 136 2010 245 256
87. S. Rakoff-Nahoum, and R. Medzhitov Regulation of spontaneous intestinal tumorigenesis through the adaptor protein MyD88 Science 317 2007 124 127 (Pubitemid 47056471)
88. J.M. Uronis, M. Mühlbauer, H.H. Herfarth, T.C. Rubinas, G.S. Jones, and C. Jobin Modulation of the intestinal microbiota alters colitis-associated colorectal cancer susceptibility PLoS One 4 6 2009 e6026 10.1371/journal.pone. 0006026
89. L. Apetoh, F. Ghiringhelli, A. Tesniere, M. Obeid, C. Ortiz, and A. Criollo Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy Nat Med 13 2007 1050 1059 (Pubitemid 47517504)
90. N.A. Marshall, K.C. Galvin, A.B. Corcoran, L. Boon, R. Higgs, and K.H.G. Mills Immunotherapy with PI3K inhibitor and Toll-like receptor agonist induces IFN-γ + IL-17 + polyfunctional T cells that mediate rejection of murine tumors Cancer Res 72 2012 581 591
91. C. Bourquin, C. Hotz, D. Noerenberg, A. Voelkl, S. Heidegger, and L.C. Roetzer Systemic cancer therapy with a small molecule agonist of Toll-like receptor 7 can be improved by circumventing TLR tolerance Cancer Res 71 2011 5123 5133
92. J.P. Butchar, P. Mehta, S.E. Justiniano, K.D. Guenterberg, S.V. Kondadasula, and X. Mo Reciprocal regulation of activating and inhibitory Fcγ receptors by TLR7/8 activation: implications for tumor immunotherapy Clin Cancer Res 16 2010 2065 2075
93. P.L. Triozzi, W. Aldrich, and S. Ponnazhagan Inhibition and promotion of tumor growth with adeno-associated virus carcinoembryonic antigen vaccine and Toll-like receptor agonists Cancer Gene Ther 18 2011 850 858
94. S. Dharmapuri, L. Aurisicchio, P. Neuner, M. Verdirame, G. Ciliberto, and N. La Monica An oral TLR7 agonist is a potent adjuvant of DNA vaccination in transgenic mouse tumor models Cancer Gene Ther 16 2009 462 472
95. C.D. Dumitru, M.A. Antonysamy, M.A. Tomai, and K.E. Lipson Potentiation of the antitumor effects of imidazoquinoline immune response modifiers by cyclophosphamide Cancer Biol Ther 10 2010 155 165
96. D. Wang, M. Precopio, T. Lan, D. Yu, J.X. Tang, and E.R. Kandimalla Antitumor activity and immune response induction of a dual agonist of Toll-like receptors 7 and 8 Mol Cancer Ther 9 2010 1788 1797
97. C. Bourquin, S. Schreiber, S. Beck, G. Hartmann, and S. Endres Immunotherapy with dendritic cells and CpG oligonucleotides can be combined with chemotherapy without loss of efficacy in a mouse model of colon cancer Int J Cancer 118 2006 2790 2795 (Pubitemid 43673358)
98. V. Damiano, R. Caputo, R. Bianco, F.P. D'Armiento, A. Leonardi, and S. De Placido Novel toll-like receptor 9agonist induces epidermal growth factor receptor (EGFR) inhibition and synergistic antitumor activity with EGFR inhibitors Clin Cancer Res 12 2006 577 583 (Pubitemid 43166152)
99. V. Damiano, R. Caputo, S. Garofalo, R. Bianco, R. Rosa, and G. Merola TLR9 agonist acts by different mechanisms synergizing with bevacizumab in sensitive and cetuximab-resistant colon cancer xenografts Proc Natl Acad Sci U S A 104 2007 12468 12473 (Pubitemid 47206161)
100. K. Heckelsmiller, K. Rall, S. Beck, A. Schlamp, J. Seiderer, and B. Jahrsdörfer PeritumoralCpG DNA elicits a coordinated response of CD8 T cells and innate effectors to cure established tumors in a murine colon carcinoma model J Immunol 169 2002 3892 3899
101. K. Heckelsmiller, S. Beck, K. Rall, B. Sipos, A. Schlamp, and E. Tuma Combined dendritic cell- and CpG oligonucleotide-based immune therapy cures large murine tumors that resist chemotherapy Eur J Immunol 32 2002 3235 3245 (Pubitemid 35414881)
102. E.R. Rayburn, W. Wang, R. Zhang, and H. Wang Experimental therapy for colon cancer: anti-cancer effects of TLR9 agonism, combination with other therapeutic modalities, and dependence upon p53 Int J Oncol 30 2007 1511 1519
103. R. Rosa, D. Melisi, V. Damiano, R. Bianco, S. Garofalo, and T. Gelardi Toll-like receptor 9 agonist Imo cooperates with cetuximab in K-Ras mutant colorectal and pancreatic cancers Clin Cancer Res 17 2011 6531 6541
104. S. Sharma, C.P. Karakousis, H. Takita, K. Shin, and S.P. Brooks Intra-tumoral injection of CpG results in the inhibition of tumor growth in murine colon-26 and B-16 tumors Biotechnol Lett 25 2003 149 153 (Pubitemid 36189361)
105. S. Sharma, C.P. Karakousis, H. Takita, K. Shin, and S.P. Brooks Cytokines and chemokines are expressed at different levels in small and large murine colon-26 tumors following intratumoral injections of CpG ODN Neoplasia 6 2004 523 528 (Pubitemid 39411088)
106. J.A. Westwood, N.M. Haynes, J. Sharkey, N. McLaughlin, H.J. Pegram, and R.A. Schwendener Toll-like receptor triggering and T-cell costimulation induce potent antitumor immunity in mice Clin Cancer Res 15 2009 7624 7633
107. C. Guiducci, A.P. Vicari, S. Sangaletti, G. Trinchieri, and M.P. Colombo Redirecting in vivo elicited tumor infiltrating macrophages and dendritic cells towards tumor rejection Cancer Res 65 2005 3437 3446 (Pubitemid 40524630)
108. A. Saha, M. Bhattacharya-Chatterjee, K.A. Foon, E. Celis, and S.K. Chatterjee Stimulatory effects of CpGoligodeoxynucleotide on dendritic cell-based immunotherapy of colon cancer in CEA/HLA-A2 transgenic mice Int J Cancer 124 2009 877 888
109. C. Zoglmeier, H. Bauer, D. Nörenberg, G. Wedekind, P. Bittner, and N. Sandholzer CpG blocks immunosuppression by myeloid-derived suppressor cells in tumor-bearing mice Clin Cancer Res 17 2011 1765 1775
110. H.A. Kim, H.M. Ko, H.W. Ju, K.J. Kim, S.G. Roh, and H.K. Lee CpG-ODN-based immunotherapy is effective in controlling the growth of metastasized tumor cells Cancer Lett 274 2009 160 164
111. I.Y. Kim, X. Yan, S. Tohme, A. Ahmed, C. Cordon-Cardo, and H.M.C.S. Kumara CpG ODN, toll like receptor (TLR)-9 agonist, inhibits metastatic colon adenocarcinoma in a murine hepatic tumor model J Surg Res 7 2011 1 7
112. S. Roux, L. Apetoh, F. Chalmin, S. Ladoire, G. Mignot, and P.E. Puig CD4 + CD25 + Tregs control the TRAIL-dependent cytotoxicity of tumor-infiltrating DCs in rodent models of colon cancer J Clin Invest 118 2008 3751 3761
113. Z.C. Hartman, T. Osada, O. Glass, X.Y. Yang, G.J. Lei, and H.K. Lyerly Ligand-independent toll-like receptor signals generated by ectopic overexpression of MyD88 generate local and systemic antitumor immunity Cancer Res 70 2010 7209 7220
114. N. Simiantonaki, U. Kurzik-Dumke, G. Karyofylli, C. Jayasinghe, R. Michel-Schmidt, and C.J. Kirkpatrick Reduced expression of TLR4 is associated with the metastatic status of human colorectal cancer Int J Mol Med 20 2007 21 29
115. T.M. Earl, I.B. Nicoud, J.M. Pierce, J.P. Wright, N.E. Majoras, and J.E. Rubin Silencing of TLR4 decreases liver tumor burden in a murine model of colorectal metastasis and hepatic steatosis Ann Surg Oncol 16 2009 1043 1050
116. R.Y.C. Hsu, C.H.F. Chan, J.D. Spicer, M.C. Rousseau, B. Giannias, and S. Rousseau LPS-induced TLR4 signaling in human colorectal cancer cells increases β1 integrin-mediated cell adhesion and liver metastasis Cancer Res 71 2011 1989 1998
117. Q. Guo, J. Zhu, and B. Xia Polymorphism of CD14 gene but not the mutation of TLR4 gene is associated with colorectal cancer in Chinese patients J Gastroenterol Hepatol 21 2006 92 97
118. S. Landi, F. Gemignani, F. Bottari, L. Gioia-Patricola, E. Guino, and M. Cambray Polymorphisms within inflammatory genes and colorectal cancer J Negat Results Biomed 5 2006 15
119. K.K. Tsilidis, K.J. Helzlsouer, M.W. Smith, V. Grinberg, J. Hoffman-Bolton, and S.L. Clipp Association of common polymorphisms in IL10, and in other genes related to inflammatory response and obesity with colorectal cancer Cancer Causes Control 20 2009 1739 1751
120. M.A. Morse, R. Chapman, J. Powderly, K. Blackwell, T. Keler, and J. Green Phase I study utilizing a novel antigen-presenting cell-targeted vaccine with Toll-like receptor stimulation to induce immunity to self antigens in cancer patients Clin Cancer Res 17 2011 4844 4853
121. ClinicalTrials.gov [Internet] Identifier NCT00719199, study of FOLFIRI plus cetuximab plus IMO-2055 in patients with colorectal cancer 2008 Jul 17 [cited 2011 Sep 25] Feb 29 2000 National Library of Medicine (US) Bethesda (MD) [Available from: http://clinicaltrials.gov/ct2/show/NCT00719199?term= NCT00719199&rank=1 ]